Analyst Reco. Teva Pharmaceutical Industries Limited OTC Markets

Equities

TEVJF

IL0006290147

Market Closed - OTC Markets Other stock markets 19:02:46 25/06/2024 BST			5-day change	1st Jan Change
14.7 ^USD	-18.33%		-18.33%	+70.53%

06-25	Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...
06-25	Teva Pharmaceutical Pays $750 Million to Resolve Tax-Related Litigation	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Teva Pharmaceutical Industries 'Well-Positioned' for Further Growth, UBS Says	06-20	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $21 From $20, Maintains Overweight Rating	06-05	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing	05-17	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing	05-15	MT
Piper Sandler Adjusts Price Target on Teva Pharmaceutical Industries to $20 From $19, Maintains Overweight Rating	05-13	MT
JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11	03-08	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts PT to $19 From $12	02-12	MT
Goldman Sachs Adjusts Price Target on Teva Pharmaceutical Industries to $11 From $10, Maintains Neutral Rating	02-05	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $17 From $15, Maintains Overweight Rating	02-05	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $15 From $14, Maintains Overweight Rating	01-29	MT
Teva: share price up, broker in support	01-23	CF
TEVA : Jefferies raises its recommendation	01-23	CF
Jefferies Upgrades Teva Pharmaceutical Industries to Buy From Hold, Raises Price Target to $14 From $10	01-23	MT
BofA Securities Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Buy Rating	01-12	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Raises Price Target to $12 From $8	01-03	MT
HSBC Initiates Teva Pharmaceutical Industries at Buy Rating With $13 Price Target	12-18	MT
UBS Upgrades Teva Pharmaceutical Industries to Buy From Neutral, Adjusts Price Target to $13 From $11	11-27	MT
UBS Upgrades Teva Pharmaceutical Industries to Neutral From Sell, Raises Price Target to $8 From $7	06/07/23	MT
Evercore ISI Upgrades Teva Pharmaceutical Industries to Outperform From In-Line	18/05/23	MT
Barclays Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Overweight Rating	09/02/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 09:41 am

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 08:19 pm